Cargando…
BIG BANG study (EPOC1703): multicentre, proof-of-concept, phase II study evaluating the efficacy and safety of combination therapy with binimetinib, encorafenib and cetuximab in patients with BRAF non-V600E mutated metastatic colorectal cancer
BACKGROUND: While the BRAF V600E mutation occurs in 5%–15% of metastatic colorectal cancer (mCRC), BRAF non-V600E mutations were recently reported to range from 1.6% to 5.1%. We have previously reported that BRAF non-V600E mutations could have a negative impact on efficacy outcomes as well as BRAF V...
Autores principales: | Kotani, Daisuke, Bando, Hideaki, Taniguchi, Hiroya, Masuishi, Toshiki, Komatsu, Yoshito, Yamaguchi, Kensei, Nakajima, Takako, Satoh, Taroh, Nishina, Tomohiro, Esaki, Taito, Nomura, Shogo, Takahashi, Koji, Iida, Shinobu, Matsuda, Seiko, Motonaga, Shinya, Fuse, Nozomu, Sato, Akihiro, Fujii, Satoshi, Ohtsu, Atsushi, Ebi, Hiromichi, Yoshino, Takayuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BMJ Publishing Group
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7046405/ https://www.ncbi.nlm.nih.gov/pubmed/33551068 http://dx.doi.org/10.1136/esmoopen-2019-000624 |
Ejemplares similares
-
Encorafenib, Binimetinib, and Cetuximab in BRAF V600E-Mutated Colorectal Cancer
por: Roviello, Giandomenico, et al.
Publicado: (2020) -
Rationale and design of the BRAVERY study (EPOC1701): a multicentre phase II study of eribulin in patients with BRAF V600E mutant metastatic colorectal cancer
por: Masuishi, Toshiki, et al.
Publicado: (2019) -
Binimetinib plus encorafenib for metastatic melanoma
Publicado: (2019) -
Encorafenib, binimetinib, and cetuximab in BRAF V600E–mutated colorectal cancer: an early post-marketing phase vigilance study
por: Sakata, Hidenori, et al.
Publicado: (2022) -
Encorafenib and Binimetinib Combination Therapy in Metastatic Melanoma
por: Davis, Jessica, et al.
Publicado: (2022)